Chinese Regulatory Changes Key To Life Sciences Investment Decisions – BioMedical Asia

SINGAPORE - Regulatory reforms during the next several years will help define the next generation of winners and losers in the China life sciences industry, and investors are anxiously parsing the landscape for any signals of how the changes might play out. But trying to predict what will come next out of a notoriously opaque regulatory process is an ongoing challenge for venture capitalists and bankers alike, as evidenced by a panel discussion on Chinese investment opportunities held March 18 during the annual BioMedical Asia conference in Singapore